This Article  • Full text  • PDF  • CME Course for This Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Renal Diseases  • Renal Diseases, Other  • Arrhythmias  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Endocrine Diseases  • Diabetes Mellitus  • Congestive Heart Failure/ Cardiomyopathy  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Treat Now by Treating Comorbidities

Sanjiv J. Shah, MD; Mihai Gheorghiade, MD

JAMA. 2008;300(4):431-433.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Heart failure (HF) is a major public health problem, with a prevalence of more than 5 million cases and an incidence of 660 000 new cases per year in the United States alone.¹Among patients older than 65 years, HF has become the most common discharge diagnosis and the primary cause of readmission within 60 days of discharge, resulting in estimated costs of $34.8 billion per year.¹ Nearly half of all patients with HF have a preserved ejection fraction (HFPEF).^2-5 Patients with HFPEF have a high all-cause mortality after hospitalization for HF: 2.9%, in-hospital mortality⁴; 9.5%, 60- to 90-day mortality⁴; 22% to 29%, 1-year mortality^2-3; and 65%, 5-year mortality.^2-3 These data underscore the urgent need to find ways to improve outcomes for these patients.

Unlike patients with HF and reduced ejection fraction, few large randomized controlled trials have been . . . [Full Text of this Article]

Author Affiliations: Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).
van Veldhuisen et al.
J Am Coll Cardiol 2009;53:2150-2158.
ABSTRACT | FULL TEXT  

Acute heart failure syndromes.
Gheorghiade and Pang
J Am Coll Cardiol 2009;53:557-573.
ABSTRACT | FULL TEXT  

Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment.
Flaherty et al.
J Am Coll Cardiol 2009;53:254-263.
ABSTRACT | FULL TEXT  

CHAPTER 23 Heart Failure
McMurray et al.
ESC Textbook of Cardiovascular Medicine 2009;2:med-9780199566990-chapter-med-9780199566990-chapter.
ABSTRACT | FULL TEXT